UBE2N and acute myeloid leukemia: Importantly, the study identifies that inhibiting TRAF6‐dependent signaling using a UBE2N inhibitor can suppress leukemic HSPCs, underscoring the therapeutic potential of targeting innate immune pathways in AML.